Protagonist Therapeutics, Inc Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
Protagonist Therapeutics, Inc (PTGX) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$27.16 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-02-25
- Protagonist Therapeutics, Inc effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$27.16M, a 146.28% decline from fiscal 2024.
- Protagonist Therapeutics, Inc effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was $58.68M.
- Protagonist Therapeutics, Inc effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2023 was -$16.58M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2025-12-31 | -$27.16M 10-K · filed 2026-02-25 |
| 2024-12-31 | $58.68M 10-K · filed 2026-02-25 |
| 2023-12-31 | -$16.58M 10-K · filed 2026-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |